MAGEA3 is an attractive immunotherapy target in multiple cancers, and its expression in sarcoma predicts that adoptive T cell therapies or cancer vaccines may be successfully applied in specific sarcoma subtypes that express this antigen. Here, MAGEA3 is linked to sarcoma.